Actively Recruiting
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
Led by University of Utah · Updated on 2026-02-13
25
Participants Needed
1
Research Sites
227 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if using topical tretinoin will help patients with solid tumors who are experiencing an acneiform rash as a side effect of their treatment. Researchers will compare the use of tretinoin on one side of the face to the use of a placebo on the other side of the face to see if there is an impact.
CONDITIONS
Official Title
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant aged 60; 18 years
- Histologically confirmed solid tumor
- Radiologically confirmed locally advanced or metastatic disease
- Eligible for and willing to receive panitumumab or cetuximab as standard care
- ECOG Performance Status 60; 2
- Adequate liver function as defined by total bilirubin 60; 1.5x ULN and AST/ALT 60; 3x ULN (up to 5x ULN allowed with liver metastases)
- Negative pregnancy test if not surgically sterilized or post-menopausal with specific hormonal status requirements
- Use of highly effective contraception if of childbearing potential or with a partner of childbearing potential
- Recovered from prior cancer treatments with acceptable adverse event levels
- Able to provide informed consent and willing to sign consent form
You will not qualify if you...
- Treatment with anti-EGFR agent within 90 days before enrollment
- Pre-existing facial rash preventing assessment of tretinoin response
- Diagnosis of another malignancy within 2 years before enrollment except certain treated cancers without current therapy
- Any condition judged by investigator to contraindicate study participation due to safety or compliance
- Active systemic infections including tuberculosis, hepatitis B (active), or hepatitis C (active)
- Medical, psychiatric, cognitive, or other issues compromising consent or protocol compliance
- Known severe allergy to study drug or its components (CTCAE grade 61; 3)
- Use of prohibited medications without adequate washout period prior to treatment start
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, United States, 84112
Actively Recruiting
Research Team
S
Susan Sharry
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here